All reports
Pharmaceutical
Obesity & Metabolic
Diabetes, NASH/MASH and Cardiometabolic Pipeline
Code: NSC/PHRM/0005Published Apr 16, 2026
About this report
Resmetirom (Rezdiffra), tirzepatide in NASH, retatrutide, Madrigal, Akero: new GLP-1 indications.
Humans at the core of the analysis
Partner specialist firms, independent domain experts and our in-house analyst team: every report is written and reviewed by humans who cross-check signals, verify sources and prioritise what matters.
Key insights
Request the sample to discover the report's key insights.
Table of contents
The detailed table of contents is shared with the free sample.